Original Query: ALL
Previous Study | Return to List | Next Study
Evaluation of Non-ablative and Fractional Combination Treatment for Improvement in Skin's Appearance
|ClinicalTrials.gov Identifier: NCT01403597|
Recruitment Status : Completed
First Posted : July 27, 2011
Last Update Posted : December 2, 2014
Information provided by (Responsible Party):
The study is designed to determine the safety, efficacy, patient comfort and patient satisfaction of the combined treatment of Refirme ST and Matrix RF both devices approved under 510k clearances. The evaluations will include skin condition, physician/subject improvement assessment, and subject comfort and satisfaction score by questionnaires.
|Condition or disease||Intervention/treatment|
|Laser Therapy Rejuvenation||Device: Refirme ST Applicator and Matrix RF Applicator|
The Refirme ST and the Matrix RF applicators are both FDA approved devices indicated for improvement of skin appearance. The Matrix RF applicator has FDA clearance for ablation, resurfacing of the skin, and for wrinkles treatment, whereas the Refirme-ST applicator has FDA clearance for non-invasive wrinkles treatment. The combined treatment of Refirme ST and Matrix RF is intended to improve skin appearance both by enhancement of collagen production as the result of the Refirme ST primary heating of the treated area and by causing ablation and resurfacing of the skin with the Matrix RF. In the current clinical setting, each applicator is used in a separate session although there is no contra-indication preventing the usage of these applicators in the same treatment session. A combined treatment in one session is believed to be more efficient and will be more time effective for the patient and therefore will have a commercial benefit for the manufacturer.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Evaluation of the Impact of Non-ablative and Fractional Ablative Combination Treatment: a Prospective, Open Label, Single Group With Before-after Study Design|
|Study Start Date :||January 2011|
|Primary Completion Date :||June 2012|
|Study Completion Date :||July 2012|
The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
Device: Refirme ST Applicator and Matrix RF Applicator
5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
Primary Outcome Measures :
- Safety of treatment [ Time Frame: 11 months ]The treatment will be considered safe if no cutaneous reactions (including excessive erythema and edema, blister formation, erosion, ulcer, scarring, infection, pruritis or allergic reactions) except of mild pigment can be detected at the site of treatment at the final follow up.
- Efficacy of Treatment [ Time Frame: 11 months ]The treatment will be considered efficacious if a result greater than ≥3 moderate to significant on GAI scale) of overall skin improvement will be marked at the final follow up
Secondary Outcome Measures :
- Patient Satisfaction [ Time Frame: 11 months ]The treatment will be considered satisfactory by the patient if a result ≥ 3 in the patient satisfaction scale will marked at the final follow up.
- Patient Comfort [ Time Frame: 11 months ]The treatment will be considered comfortable if a result ≥ 2 in the patient comfort assessment scale will marked at the end of at least 3/5 or 2/4 treatments.
No Contacts or Locations Provided